Policy Pulse — Trump/US — 31 Jul 2026
💊 Section 232 Pharmaceutical Tariffs Take Effect Today — Branded Drugs at 100%, Generics Exempt
The July 31, 2026 deadline hit today for Trump's Pharmaceutical Section 232 tariffs, imposed under the Trade Expansion Act of 1962. The tariffs apply additional duties of up to 100% on patented brand-name pharmaceuticals and their active ingredients (APIs) imported into the United States.
The key nuance — this is NOT a blanket pharma tariff:
- 17 named companies (Annex III) — mostly the large global branded drugmakers — face the 100% duty from today (Jul 31). However, most of these have secured tariff exemptions via "MFN pricing agreements" or the 20% onshoring incentive — companies that commit to shifting production to the US can reduce the rate to 20%.
- Generics and biosimilars are EXPRESSLY EXCLUDED from the Section 232 duties — both in the proclamation and via the India-US negotiated deal that favors generic drugmakers.
- EU, Japan, Korea face a tiered 15% rate; UK at 10%.
- A second, broader deadline for all other importers arrives Sept 29, 2026.
Stocks to Watch
| Stock | Impact | Reason |
|---|---|---|
| LLY | 🟢 Positive | Branded pharma — protected from import competition, MFN/onshoring deal softens rate |
| MRK | 🟢 Positive | Branded drug leader — direct beneficiary of tariff wall against foreign generics |
| JNJ | 🟢 Positive | Diversified branded pharma — competitive protection is structural positive |
| PFE | 🟢 Positive | Innovator pharma — high-price branded drugs insulated |
| ABBV | 🟢 Positive | Branded specialty pharma — Humira etc. protected from low-cost entrants |
| UNH | 🟡 Hold | Managed care/healthcare — broader healthcare pricing backdrop mixed |
| GILD | 🟡 Hold | Branded but specialty — limited direct exposure, watch Sept 29 list |
Key insight: The Section 232 pharma tariff is structurally protective for US branded/innovator pharma (LLY, MRK, JNJ, PFE, ABBV) — it erects a 100% wall against foreign patented drugs while exempting generics. The "20% onshoring incentive" rewards US manufacturing, a positive for durability of US pharma earnings. The wildcard is the Sept 29 expansion to all importers.
🇨🇦 Canada 50% Section 338 Tariffs — Approaching Effective Date (Mid-Aug)
Trump's Section 338 tariffs on Canadian autos, alcohol, and dairy ($20B, 50%) — invoked under the 1930 Tariff Act, first use in ~100 years — approach their effective date (30 days from the Jul 20 signing = mid-Aug 2026). No new action today, but the countdown continues.
| Stock | Impact | Reason |
|---|---|---|
| F | 🟡 Hold | US auto exposure to Canadian supply chains — watch mid-Aug trigger |
| GM | 🟡 Hold | Same — cross-border auto tariff risk |
| TAP | 🔴 Negative | Alcohol import exposure — Canadian/liquor tariff hit |
| STZ | 🔴 Negative | Imported beer/wine/liquor costs rise |
📊 Fed / Macro — Crude Easing, Market Stabilizing After Yield Shock
After the Jul 29 Fed hawkish hold sent 30-yr yields to 2007 highs, markets are stabilizing. Crude has eased off the Hormuz spike, supporting a modest risk-on tone into week's end. Indian finance ministry and RBI monitor the USD/INR (rupee at a 3-week high ~95.4/$).
| Stock | Impact | Reason |
|---|---|---|
| SPY | 🟡 Hold | Stabilizing after yield spike — watch Sept FOMC |
| QQQ | 🟡 Hold | Tech steady as crude eases, but yields still elevated |
| XOM | 🟡 Hold | Crude easing off highs — oil gains partial |
| CVX | 🟡 Hold | Same — energy consolidating |
Summary
Today's dominant US signal is the Pharma Section 232 tariff taking effect (Jul 31) — a durable structural BUY for US branded/innovator pharma (LLY, MRK, JNJ, PFE, ABBV) and a confirmed exemption for generics, defusing the Jul 22 generic-tariff scare. Watch Sept 29 for the all-importer expansion and mid-Aug for the Canada 50% Section 338 tariffs.
Tickers in focus: LLY, MRK, JNJ, PFE, ABBV